+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skeletal Dysplasia - Global Strategic Business Report 2026

  • PDF Icon

    Report

  • 378 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6071411
The global market for Skeletal Dysplasia was valued at US$3.3 Billion in 2025 and is projected to reach US$3.7 Billion by 2032, growing at a CAGR of 1.7% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Skeletal Dysplasia Market - Key Trends & Drivers Summarized Why Is Skeletal Dysplasia Gaining Attention in Rare Disease Research? Understanding Its Impact and Medical Challenges
Skeletal dysplasia, a group of over 400 rare genetic disorders affecting bone growth and development, has become an important area of focus in medical research and treatment innovation. These conditions can lead to dwarfism, joint abnormalities, and severe skeletal deformities, impacting mobility and overall quality of life. As awareness of rare diseases increases, healthcare systems are investing in early diagnosis, genetic counseling, and novel therapeutic approaches to manage skeletal dysplasia more effectively. Advances in genetic sequencing have improved diagnostic accuracy, allowing for better disease classification and personalized treatment strategies. Pediatric orthopedic interventions, such as limb-lengthening surgeries and growth hormone therapies, have also expanded treatment options, offering improved mobility and functional independence for affected individuals. The rising number of clinical trials for targeted therapies is further enhancing prospects for disease management and potential cures.

How Are Technological Advancements Improving Skeletal Dysplasia Diagnosis and Treatment? Exploring Innovations in Genetics and Regenerative Medicine
Technological breakthroughs in genomics, regenerative medicine, and orthopedic surgery have significantly enhanced the diagnosis and treatment of skeletal dysplasia. Whole-exome and whole-genome sequencing have enabled precise genetic identification of skeletal dysplasia subtypes, leading to earlier interventions and better patient outcomes. Advanced imaging technologies, such as 3D CT scans and MRI-based bone modeling, have improved pre-surgical planning for complex orthopedic procedures. In regenerative medicine, stem cell therapy and tissue engineering are being explored as potential treatments to stimulate bone growth and repair structural abnormalities. Additionally, the development of CRISPR gene-editing technology has raised hopes for correcting genetic mutations responsible for skeletal dysplasia, although this approach is still in its experimental stages. As research progresses, these technological innovations are expected to revolutionize the way skeletal dysplasia is diagnosed and managed.

What Challenges Are Hindering the Treatment of Skeletal Dysplasia? Addressing Accessibility, Costs, and Ethical Concerns
Despite medical advancements, the treatment of skeletal dysplasia faces challenges related to accessibility, high treatment costs, and ethical considerations in genetic research. Many rare disease treatments are expensive, limiting access for patients in low-income regions where specialized medical care is scarce. Additionally, surgical interventions and growth hormone therapies require long-term follow-ups, placing a financial burden on healthcare systems and families. The complexity of skeletal dysplasia also presents challenges in drug development, as effective treatments must target diverse genetic mutations while minimizing potential side effects. Ethical concerns surrounding gene-editing research further complicate the development of genetic therapies, as regulatory frameworks for rare disease treatments continue to evolve. Addressing these challenges requires greater investment in affordable treatment options, expanded patient support programs, and international collaboration to advance research in skeletal dysplasia therapies.

What's Driving the Growth of the Skeletal Dysplasia Market? Identifying Key Expansion Factors and Research Trends
The growth in the skeletal dysplasia market is driven by several factors, including increasing rare disease research funding, advancements in genetic diagnostics, and expanding treatment options in pediatric orthopedics. Governments and research institutions worldwide are prioritizing skeletal dysplasia research as part of broader rare disease initiatives, leading to more funding for clinical trials and drug development. The growing use of gene therapy and biologics in musculoskeletal disorders has also opened new therapeutic possibilities for skeletal dysplasia patients. Additionally, improvements in assistive technologies, such as exoskeletons and orthopedic implants, have enhanced mobility solutions for individuals with severe skeletal abnormalities. The rise of patient advocacy groups and increased public awareness have further contributed to market growth by encouraging better healthcare policies and access to innovative treatments. As genetic and regenerative medicine advances continue to evolve, the skeletal dysplasia market is expected to see significant progress in developing long-term solutions for affected individuals.

Report Scope
The report analyzes the Skeletal Dysplasia market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
- Segments: Disorder Type (X-linked Hypophosphatemia, Hypophosphatasia, Achondroplasia, Fibrodysplasia Ossificans Progressive, Multiple Osteochondromas); Treatment (Medication, Surgery); Symptom (Skeletal Deformities, Dental Deformities, Others).
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the X-linked Hypophosphatemia segment, which is expected to reach US$1.6 Billion by 2032 with a CAGR of a 1.7%. The Hypophosphatasia segment is also set to grow at 2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $896.2 Million in 2025, and China, forecasted to grow at an impressive 3% CAGR to reach $679.6 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Skeletal Dysplasia Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Skeletal Dysplasia Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Skeletal Dysplasia Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Skeletal Dysplasia market report include:
- AbbVie Inc.- Alexion Pharmaceuticals Inc.- Amgen Inc.- Astellas Pharma Inc.- AstraZeneca plc- Bayer AG- Biogen Inc.- BioMarin Pharmaceutical Inc.- Boehringer Ingelheim GmbH- BridgeBio Pharma- Bristol-Myers Squibb Company- Cipla Ltd.- Clementia Pharmaceuticals (Ipsen)- Eli Lilly and Company- F. Hoffmann-La Roche AG- GlaxoSmithKline plc- Ipsen S.A.- Johnson & Johnson- Kyowa Kirin Co., Ltd.- Merck KGaA- Novartis International AG- Novo Nordisk A/S- Pfizer Inc.- Regeneron Pharmaceuticals Inc.- Sanofi S.A.- Shire plc (now part of Takeda)- Takeda Pharmaceutical Company Ltd.- Teva Pharmaceutical Industries Ltd.- Ultragenyx Pharmaceutical Inc.- Vertex Pharmaceuticals Inc.
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Skeletal Dysplasia - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Awareness of Rare Genetic Disorders Throws the Spotlight on Early Diagnosis and Management of Skeletal Dysplasia
  • Expansion of Genomic Sequencing Capabilities Drives Identification of Novel Mutations and Subtypes
  • OEM Innovation in 3D Imaging, MRI, and Radiographic Tools Enhances Diagnostic Accuracy and Classification
  • Growth in Multidisciplinary Care Models Spurs Demand for Coordinated Treatment Across Orthopedic and Genetic Specialties
  • OEM Development of Pediatric-Focused Surgical Instruments and Orthopedic Implants Supports Condition-Specific Interventions
  • Increasing Use of Whole Exome Sequencing in Prenatal and Neonatal Settings Drives Early Detection of Skeletal Abnormalities
  • OEM Collaboration With Genetic Counseling Providers Strengthens Family Support and Diagnostic Pathways
  • Rising Availability of Disease Registries and Patient Advocacy Resources Expands Access to Targeted Therapies
  • OEM Research in FGFR3 and COL2A1 Pathways Strengthens the Pipeline for Pharmacologic Interventions
  • Surge in Customized Bracing and Mobility Aids Enhances Functional Quality of Life in Pediatric and Adult Patients
  • OEM Focus on Non-Invasive Growth Modulation Technologies Offers Alternatives to Limb-Lengthening Surgeries
  • Growth in Rare Disease Awareness Campaigns Promotes Public and Policy-Level Support for Reimbursement
  • OEM Emphasis on Cell and Gene Therapies Unlocks Long-Term Treatment Potential for Monogenic Dysplasias
  • Rising Integration of AI Tools in Radiological Screening Expedites Phenotypic Classification of Skeletal Disorders
  • OEM Development of Dwarfism-Friendly Medical Devices and Anesthesia Protocols Supports Specialized Care
  • Expansion of National Centers of Excellence for Rare Bone Disorders Strengthens Institutional Expertise
  • OEM Focus on Patient-Reported Outcomes and Longitudinal Monitoring Enhances Treatment Personalization
  • Growing Emphasis on Inclusive Infrastructure and Mobility Rights Drives Demand for Assistive Technology
  • OEM Investment in Disease Modeling Using Organoids and CRISPR Systems Accelerates Drug Discovery Pipelines
  • Focus on Multigenerational Genetic Testing and Carrier Screening Supports Preventive Health Strategies
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Skeletal Dysplasia Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Skeletal Dysplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Skeletal Dysplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Skeletal Dysplasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for X-linked Hypophosphatemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for X-linked Hypophosphatemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for X-linked Hypophosphatemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Hypophosphatasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Hypophosphatasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Hypophosphatasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Achondroplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Achondroplasia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Achondroplasia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Fibrodysplasia Ossificans Progressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Fibrodysplasia Ossificans Progressive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Fibrodysplasia Ossificans Progressive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Multiple Osteochondromas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Multiple Osteochondromas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Multiple Osteochondromas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Skeletal Deformities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Skeletal Deformities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Skeletal Deformities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Dental Deformities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Dental Deformities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Dental Deformities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
AUSTRALIA
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Skeletal Dysplasia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • BridgeBio Pharma
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Clementia Pharmaceuticals (Ipsen)
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Ipsen S.A.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • Shire plc (now part of Takeda)
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Vertex Pharmaceuticals Inc.

Table Information